SCHEMBL5548715

SCHEMBL5548715

CC(C)(C)OC(=O)NC1CCC(CS(=O)(=O)c2ccccc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.52
KDM1A O60341 1/20 0.52
DRD2 P14416 4/20 0.52
KMT2A Q03164 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
BTK Q06187 1/20 0.46
CCR5 P51681 1/20 0.46
EPHX2 P34913 1/20 0.44
ACACB O00763 1/20 0.43
KCNA3 P22001 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
DRD3 P35462 1/20 0.43
KAT8 Q9H7Z6 1/20 0.42
MMP13 P45452 2/20 0.42
ATM Q13315 1/20 0.41
MAOA P21397 1/20 0.41
CKS1B P61024 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5548711 1.00 MAOB (0.52) MAOBKDM1ADRD2KMT2AL3MBTL1
SCHEMBL5543212 1.00 MAOB (0.52) MAOBKDM1ADRD2KMT2AL3MBTL1
SCHEMBL4419851 0.85 CCR2 (0.54) MAOBKDM1ADRD2KMT2AL3MBTL1
SCHEMBL12688390 0.82 DRD2 (0.46) MAOBKDM1ADRD2KMT2AL3MBTL1
SCHEMBL12688463 0.82 DRD2 (0.46) MAOBKDM1ADRD2KMT2AL3MBTL1
SCHEMBL21089801 0.81 KMT2A (0.59) MAOBKDM1ADRD2KMT2AL3MBTL1
SCHEMBL3904285 0.81 KMT2A (0.59) MAOBKDM1ADRD2KMT2AL3MBTL1
SCHEMBL28426812 0.81 BTK (0.50) MAOBKDM1ADRD2KMT2AL3MBTL1
SCHEMBL29470586 0.81 BTK (0.50) MAOBKDM1ADRD2KMT2AL3MBTL1
SCHEMBL12688482 0.81 RORC (0.44) MAOBKDM1ADRD2KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050192324-A1 Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof GLENMARK PHARMACEUTICALS LTD. (IN) 2005-09-01 US claimed
US-7230002-B2 Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof GLENMARK PHARMACEUTICALS LTD. (IN) 2007-06-12 US disclosed
US-20050192324-A1 Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof GLENMARK PHARMACEUTICALS LTD. (IN) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192324-A1 Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof DPP4, DPP3, DPP7 MAOB 2337/4885KDM1A 2466/4885DRD2 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.